Hematopoietic stem cells for early-onset type I diabetes mellitus
This study aims to evaluate the effect of inactivation of the immune system, with chemotherapy and immunotherapy, in conjunction with infusion of peripheral blood-derived hematopoietic stem cells (peripheral blood-HSCs) in early onset type 1 diabetes mellitus patients. Following treatment, c-peptide levels increased significantly and the majority of patients achieved insulin independence with good glycemic control.
Read More
Product Information for
Hematopoietic stem cells for early-onset type I diabetes mellitus